Diabetes Drug Can Cut Risk of Kidney Stones

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors- a class of diabetic medications, in type 2 diabetes patients is associated with a reduced risk of kidney stone development compared to other classes of diabetes medications. These findings were revealed by researchers at Mass General Brigham and published in JAMA Internal Medicine (1^✔ ✔Trusted Source
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes

Go to source

).

Kidney Benefits of SGLT2 Inhibitors in Type 2 Diabetics

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with an increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering the risk of kidney stones.
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital, founding members of the Mass General Brigham healthcare system, worked together to conduct the analysis. The study included data from three nationwide databases of patients with type 2 diabetes who were seen in routine clinical practice.

The team analyzed information from 716,406 adults with type 2 diabetes who had started taking an SGLT2 inhibitor or two other classes of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.

Patients who began taking SGLT2 inhibitors had a 30 percent lower risk of developing kidney stones than those taking GLP1 agonists and about a 25 percent lower risk than those taking DPP4 inhibitors. The findings were consistent across sex, race/ethnicity, history of chronic kidney disease, and obesity.

“Our findings could help inform clinical decision-making for patients with diabetes who are at risk for developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medicine at Brigham and Women’s Hospital.

Reference:

1. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes – (https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2814491)

Source-Eurekalert